De Clercq, E. et al. published their research in Life Sciences in 1986 | CAS: 69256-17-3

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.SDS of cas: 69256-17-3

Mutagenic potential of anti-herpes agents was written by De Clercq, E.; Cassiman, J. J.. And the article was included in Life Sciences in 1986.SDS of cas: 69256-17-3 The following contents are mentioned in the article:

A number of anti-herpes agents which are either licensed for clin. use (acyclovir  [59277-89-3]) or subject of clin. studies (bromovinyldeoxyuridine  [82768-44-3], fluoroiodoaracytidine  [69123-90-6], dihydroxypropoxymethylguanine  [82410-32-0]) or under preclin. investigation (i.e., fluoroiodoarauridine  [69123-98-4]), fluoromethylarauridine  [69256-17-3], dihydroxybutylguanine  [83470-64-8], bromovinyldeoxycytidine  [84412-83-9], bromovinylarauridine  [77181-69-2], and carbocyclic bromovinyldeoxyuridine  [95463-56-2]) were evaluated for their ability to induce sister chromatid exchange (SCE), an indicator of mutagenesis. SCE was scored on metaphasic chromosomes of human lymphocytes which had been exposed to 5-bromo-2-deoxyuridine and varying concentrations of the test compounds The antiviral assays were based on the inhibition of the cytopathogenicity of herpes simplex virus for human diploid fibroblasts. Most compounds, i.e. acyclovir, bromovinyldeoxyuridine, or carbocyclic bromovinyldeoxyuridine, did either not induce SCE or only so at concentrations far above their min. antiviral concentrations However, fluoroiodoaracytidine and dihydroxypropoxymethylguanine affected the SCE rate at a concentration (≥ 4.5 μg/mL) that is readily achievable in blood following i.v. injection. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3SDS of cas: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.SDS of cas: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3